^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Published date:
05/14/2021
Excerpt:
Median follow-up was 55·7 months (IQR 41·0–77·3)….adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide (median overall survival 82·3 months [95% CI 67·2–116·6] vs 46·9 months [37·9–56·9]; HR 0·64 [95% CI 0·52–0·79], p<0·0001)....Clinical benefit was dependent on IDH1 and IDH2 mutational status.
DOI:
https://doi.org/10.1016/S1470-2045(21)00090-5
Trial ID:
Source:
Title:
A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastoma
Excerpt:
...Se l'IHC viene eseguito ed è negativo, e il paziente ha < 55 anni, è necessario eseguire il sequenziamento o un test convalidato basato sulla PCR per escludere altre mutazioni IDH1 o IDH2 più frequenti.4. ...
Trial ID:
